NCT02220829View on ClinicalTrials.gov

Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2023

Study Completion Date

August 31, 2023

Conditions
Urinary ProblemsProstate Cancer
Interventions
DRUG

Preventive administration of Rapaflo

Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.

DRUG

Standard Care

Administration of alpha-blocker Rapaflo only at onset of symptoms.

Trial Locations (1)

H3T 1E2

Jewish General Hospital, McGill University, Montreal

All Listed Sponsors
lead

Sir Mortimer B. Davis - Jewish General Hospital

OTHER

NCT02220829 - Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy | Biotech Hunter | Biotech Hunter